77 related articles for article (PubMed ID: 22572578)
21. Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acids.
Leonard K; Pan W; Anaclerio B; Gushue JM; Guo Z; DesJarlais RL; Chaikin MA; Lattanze J; Crysler C; Manthey CL; Tomczuk BE; Marugan JJ
Bioorg Med Chem Lett; 2005 May; 15(10):2679-84. PubMed ID: 15863341
[TBL] [Abstract][Full Text] [Related]
22. The constrained amino acid beta-Acc confers potency and selectivity to integrin ligands.
Urman S; Gaus K; Yang Y; Strijowski U; Sewald N; De Pol S; Reiser O
Angew Chem Int Ed Engl; 2007; 46(21):3976-8. PubMed ID: 17394270
[No Abstract] [Full Text] [Related]
23. Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.
Del Gatto A; Zaccaro L; Grieco P; Novellino E; Zannetti A; Del Vecchio S; Iommelli F; Salvatore M; Pedone C; Saviano M
J Med Chem; 2006 Jun; 49(11):3416-20. PubMed ID: 16722662
[TBL] [Abstract][Full Text] [Related]
24. Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity.
Neubauer S; Rechenmacher F; Brimioulle R; Di Leva FS; Bochen A; Sobahi TR; Schottelius M; Novellino E; Mas-Moruno C; Marinelli L; Kessler H
J Med Chem; 2014 Apr; 57(8):3410-7. PubMed ID: 24654918
[TBL] [Abstract][Full Text] [Related]
25. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids.
Belvisi L; Bernardi A; Colombo M; Manzoni L; Potenza D; Scolastico C; Giannini G; Marcellini M; Riccioni T; Castorina M; LoGiudice P; Pisano C
Bioorg Med Chem; 2006 Jan; 14(1):169-80. PubMed ID: 16214345
[TBL] [Abstract][Full Text] [Related]
26. Discovery of orally available integrin alpha5beta1 antagonists.
Zischinsky G; Osterkamp F; Vossmeyer D; Zahn G; Scharn D; Zwintscher A; Stragies R
Bioorg Med Chem Lett; 2010 Jan; 20(1):380-2. PubMed ID: 19910191
[TBL] [Abstract][Full Text] [Related]
27. Synthetic RGD-containing alpha-helical coiled coil peptides promote integrin-dependent cell adhesion.
Villard V; Kalyuzhniy O; Riccio O; Potekhin S; Melnik TN; Kajava AV; Rüegg C; Corradin G
J Pept Sci; 2006 Mar; 12(3):206-12. PubMed ID: 16103993
[TBL] [Abstract][Full Text] [Related]
28. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
Demirgöz D; Garg A; Kokkoli E
Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
[TBL] [Abstract][Full Text] [Related]
29. Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin.
Schwarz MA; Zheng H; Liu J; Corbett S; Schwarz RE
Exp Cell Res; 2005 Dec; 311(2):229-39. PubMed ID: 16248999
[TBL] [Abstract][Full Text] [Related]
30. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.
Zahn G; Volk K; Lewis GP; Vossmeyer D; Stragies R; Heier JS; Daniel PE; Adamis AP; Chapin EA; Fisher SK; Holz FG; Löffler KU; Knolle J
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1028-35. PubMed ID: 19815730
[TBL] [Abstract][Full Text] [Related]
31. Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.
Sundaram A; Chen C; Isik Reed N; Liu S; Ki Yeon S; McIntosh J; Tang YZ; Yang H; Adler M; Beresis R; Seiple IB; Sheppard D; DeGrado WF; Jo H
Bioorg Med Chem Lett; 2020 Nov; 30(22):127578. PubMed ID: 33007395
[TBL] [Abstract][Full Text] [Related]
32. Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent integrins.
Takagi J
Biochem Soc Trans; 2004 Jun; 32(Pt3):403-6. PubMed ID: 15157147
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationships of RGD mimetics as fibrinogen-receptor antagonists.
Miyashita M; Akamatsu M; Ueno H; Nakagawa Y; Nishimura K; Hayashi Y; Sato Y; Ueno T
Biosci Biotechnol Biochem; 1999 Oct; 63(10):1684-90. PubMed ID: 10586496
[TBL] [Abstract][Full Text] [Related]
34. Mechanically activated integrin switch controls alpha5beta1 function.
Friedland JC; Lee MH; Boettiger D
Science; 2009 Jan; 323(5914):642-4. PubMed ID: 19179533
[TBL] [Abstract][Full Text] [Related]
35. Functionalizing αvβ3- or α5β1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro.
Rechenmacher F; Neubauer S; Polleux J; Mas-Moruno C; De Simone M; Cavalcanti-Adam EA; Spatz JP; Fässler R; Kessler H
Angew Chem Int Ed Engl; 2013 Jan; 52(5):1572-5. PubMed ID: 23345131
[No Abstract] [Full Text] [Related]
36. Synthesis of a non-peptidic PET tracer designed for α5β1 integrin receptor.
Monaco A; Michelin O; Prior J; Rüegg C; Scapozza L; Seimbille Y
J Labelled Comp Radiopharm; 2014 May; 57(5):365-70. PubMed ID: 24634266
[TBL] [Abstract][Full Text] [Related]
37. ProteoChip-based library screening of integrin alpha5beta1 antagonists from Korean medicinal plant extracts.
Bang JI; Kim EY; Seong NS; Shin YS; Kang IC
Arch Pharm Res; 2007 Dec; 30(12):1584-9. PubMed ID: 18254246
[TBL] [Abstract][Full Text] [Related]
38. Activation of integrin alpha5beta1 delays apoptosis of Ntera2 neuronal cells.
Gibson RM; Craig SE; Heenan L; Tournier C; Humphries MJ
Mol Cell Neurosci; 2005 Mar; 28(3):588-98. PubMed ID: 15737747
[TBL] [Abstract][Full Text] [Related]
39. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.
Lin Kc; Ateeq HS; Hsiung SH; Chong LT; Zimmerman CN; Castro A; Lee WC; Hammond CE; Kalkunte S; Chen LL; Pepinsky RB; Leone DR; Sprague AG; Abraham WM; Gill A; Lobb RR; Adams SP
J Med Chem; 1999 Mar; 42(5):920-34. PubMed ID: 10072689
[TBL] [Abstract][Full Text] [Related]
40. Enhanced integrin mediated signaling and cell cycle progression on fibronectin mimetic peptide amphiphile monolayers.
Shroff K; Pearce TR; Kokkoli E
Langmuir; 2012 Jan; 28(3):1858-65. PubMed ID: 22149259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
